Pharmacology, Toxicology and Pharmaceutical Science
Prospective Study
100%
Normal Human
100%
Hemostatic Agent
100%
Von Willebrand Factor
100%
Tissue Plasminogen Activator
77%
Endothelial Dysfunction
33%
Fibrinogen
11%
Cardiovascular Risk
11%
Atherosclerosis
11%
Blood Clotting Factor 7
11%
Plasminogen Activator Inhibitor
11%
Coronary Artery Atherosclerosis
11%
Medicine and Dentistry
Prospective Study
100%
Urinary System
100%
Hemostat
100%
Von Willebrand Factor
81%
Tissue Plasminogen Activator
63%
Endothelial Dysfunction
27%
Fibrinogen
9%
Cardiovascular Risk
9%
Atherosclerosis
9%
Volunteer
9%
Endothelial Cell
9%
Patient with Diabetes
9%
Plasminogen Activator Inhibitor
9%
Factor VII
9%
Keyphrases
Urinary Albumin Excretion
100%
Hemostatic Factors
100%
Von Willebrand Factor
81%
Tissue Plasminogen Activator (t-PA)
63%
Microgram
27%
Plasma Concentration
18%
Endothelial Dysfunction
18%
Fibrinogen
9%
Risk Factors
9%
No Significant Difference
9%
Healthy Volunteers
9%
Cardiovascular Risk
9%
Patients with Diabetes
9%
Endothelial Cells
9%
Between-subject
9%
Plasminogen Activator inhibitor-1 (PAI-1)
9%
Atherosclerotic Cardiovascular Disease (ASCVD)
9%
Hemostatic Function
9%
High Concentration
9%
Markers of Endothelial Dysfunction
9%
Inhibitor Factor
9%
Biochemistry, Genetics and Molecular Biology
Prospective Study
100%
Normal Human
100%
Von Willebrand Factor
100%
Tissue Plasminogen Activator
77%
Blood Level
22%
Fibrinogen
11%
Factor VII
11%
Plasminogen Activator Inhibitor-1
11%
Immunology and Microbiology
Normal Human
100%
Blood Level
50%
Atherosclerosis
25%
Fibrinogen
25%
Tissue Factor
25%